| Antelope Memorial Hospital | |
| P O Box 229, 102 West 9th St, Neligh, Nebraska 68756 | |
| (402) 887-4151 | |
| Not Available |
| Name | Antelope Memorial Hospital |
|---|---|
| Type | Critical Access Hospital |
| Location | P O Box 229, 102 West 9th St, Neligh, Nebraska |
| Ownership | Voluntary non-profit - Private |
| Emergency Services | Yes |
| Medicare ID (CCN) | 281326 |
| NPI Number | 1083790893 |
| Organization Name | ANTELOPE MEMORIAL HOSPITAL |
| Address | 102 W 9th St, Neligh, NE 68756 |
| Hospital Type | General Acute Care Hospital - Critical Access |
| Phone Number | 402-887-4151 |
News Archive
Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone metastasis in humans.
Raydiance, Inc., the world's leading developer of ultrafast laser technology, announced today that it has demonstrated the ability to machine precise, micron-resolution features in gold and platinum, two of the more difficult-to-process materials used in advanced medical devices. Raydiance engineers achieved the results using the company's Smart LightTM 50 femtosecond pulse laser integrated into a Rofin StarCut Tube workstation.
The COVID-19 pandemic has continued to cause dramatic shifts in the practice of otolaryngology. Even with standard precautions such as physical distancing and wearing personal protective equipment, aerosol-generating procedures such as nasolaryngoscopy (a commonly performed in-office procedure in which a soft, flexible fiber-scope is passed through the nose and into the throat) and intranasal instrumentation were determined to carry a risk of potential transmission if not adequately protected.
ev3 Inc., a global endovascular device company, today reported financial results for its fiscal first quarter and updated financial guidance for 2010. ev3's net sales totaled $123.9 million in the first quarter of 2010 compared to $100.4 million in the same quarter of the prior year. Excluding $2.9 million of positive impact due to foreign currency exchange rates, net sales increased 21% versus the prior year quarter.
Researchers at the Cummings School of Veterinary Medicine have received U.S. patent approval for an antibody-based treatment for Hemolytic Uremic Syndrome (HUS), a potentially fatal outcome of E. coli poisoning and the leading cause of kidney failure in children.
› Verified 3 days ago
| NPI Number | 1710142195 |
| Organization Name | ANTELOPE MEMORIAL HOSPITAL |
| Address | 102 West 9th St, Box 229, Neligh, NE 68756 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 402-887-4151 |
News Archive
Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone metastasis in humans.
Raydiance, Inc., the world's leading developer of ultrafast laser technology, announced today that it has demonstrated the ability to machine precise, micron-resolution features in gold and platinum, two of the more difficult-to-process materials used in advanced medical devices. Raydiance engineers achieved the results using the company's Smart LightTM 50 femtosecond pulse laser integrated into a Rofin StarCut Tube workstation.
The COVID-19 pandemic has continued to cause dramatic shifts in the practice of otolaryngology. Even with standard precautions such as physical distancing and wearing personal protective equipment, aerosol-generating procedures such as nasolaryngoscopy (a commonly performed in-office procedure in which a soft, flexible fiber-scope is passed through the nose and into the throat) and intranasal instrumentation were determined to carry a risk of potential transmission if not adequately protected.
ev3 Inc., a global endovascular device company, today reported financial results for its fiscal first quarter and updated financial guidance for 2010. ev3's net sales totaled $123.9 million in the first quarter of 2010 compared to $100.4 million in the same quarter of the prior year. Excluding $2.9 million of positive impact due to foreign currency exchange rates, net sales increased 21% versus the prior year quarter.
Researchers at the Cummings School of Veterinary Medicine have received U.S. patent approval for an antibody-based treatment for Hemolytic Uremic Syndrome (HUS), a potentially fatal outcome of E. coli poisoning and the leading cause of kidney failure in children.
› Verified 3 days ago
| Able to receive lab results electronically | Not Available |
| Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone metastasis in humans.
Raydiance, Inc., the world's leading developer of ultrafast laser technology, announced today that it has demonstrated the ability to machine precise, micron-resolution features in gold and platinum, two of the more difficult-to-process materials used in advanced medical devices. Raydiance engineers achieved the results using the company's Smart LightTM 50 femtosecond pulse laser integrated into a Rofin StarCut Tube workstation.
The COVID-19 pandemic has continued to cause dramatic shifts in the practice of otolaryngology. Even with standard precautions such as physical distancing and wearing personal protective equipment, aerosol-generating procedures such as nasolaryngoscopy (a commonly performed in-office procedure in which a soft, flexible fiber-scope is passed through the nose and into the throat) and intranasal instrumentation were determined to carry a risk of potential transmission if not adequately protected.
ev3 Inc., a global endovascular device company, today reported financial results for its fiscal first quarter and updated financial guidance for 2010. ev3's net sales totaled $123.9 million in the first quarter of 2010 compared to $100.4 million in the same quarter of the prior year. Excluding $2.9 million of positive impact due to foreign currency exchange rates, net sales increased 21% versus the prior year quarter.
Researchers at the Cummings School of Veterinary Medicine have received U.S. patent approval for an antibody-based treatment for Hemolytic Uremic Syndrome (HUS), a potentially fatal outcome of E. coli poisoning and the leading cause of kidney failure in children.
› Verified 3 days ago
Antelope Memorial Hospital Critical Access Hospital Location: P O Box 229, 102 West 9th St, Neligh, Nebraska 68756 Phone: (402) 887-4151 |